thelancet.com
Jun 12, 2025, 05:36
The Lancet Haematology – Extended Anticoagulation in Children with VTE: New Insights from the EINSTEIN-Jr Trial
The Lancet Haematology shared on X:
“A cohort study within the EINSTEIN-Jr trial explores extended-phase anticoagulation for acute VTE in children:
Key factors: symptomatic index VTE, unprovoked VTE, & residual thrombosis.
Low risk of recurrent VTE & no major bleeding.”
Title: Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial.
Autors: Christoph Male, Anthonie W A Lensing, Anthony K C Chan, Gili Kenet, Guy Young, Rukhmi Bhat, Akos F Pap, Dagmar Kubitza, Martin H Prins, Paul Monagle.

Here are some of the most compelling recent updates on Hemostasis Today
Akos F Pap
Anthonie W A Lensing
Anthony K C Chan
Anticoagulation Safety
Bleeding Risk in Children
Christoph Male
Dagmar Kubitza
EINSTEIN-Jr Trial
Extended-phase Anticoagulation
Gili Kenet
Guy Young
Headlines
Hemostasis Today
Martin H Prins
Paul Monagle
Pediatric Hemostasis
Pediatric Venous Thromboembolism
Recurrent Thrombosis Risk
Residual Thrombosis
Rukhmi Bhat
Symptomatic VTE
The Lancet Haematology
Unprovoked VTE in Children
-
Sep 22, 2026, 17:49Nirav Dhanesha: Targeting FXI for Safer Anticoagulation
-
Sep 22, 2026, 17:17Eric Lambert: Intravascular Imaging and the Future of Precision PCI
-
Sep 22, 2026, 16:45Claudiu Stoicescu: Are We Starting Cardiovascular Risk Assessment Too Late?
-
Sep 22, 2026, 16:35Complement – Coagulation Crosstalk in Thrombosis
-
Sep 22, 2026, 16:20Ila Bappa Ibrahim: Bringing Sickle Cell Innovation Closer to Communities
-
Sep 22, 2026, 16:02Ana Pedrero Gil: Peri-operative Management of Patients Undergoing Day Surgery
-
Sep 22, 2026, 15:27Zia Ullah: RBC-Derived Extracellular Vesicles as Potential Biomarkers of Thrombotic Risk in Dengue
-
Sep 22, 2026, 15:01Lesley Van Wyk: What Each Iron Markers Actually Mean
-
Sep 22, 2026, 14:37Chokri Ben Lamine։ Saudi Arabia Leads A New Milestone In Hemophilia A Care